Asset profile
bezuclastinib · Cogent (COGT)
- Indication
- Gastrointestinal Stromal Tumors (GIST) after prior imatinib
- Also known as
- CGT4255, bezuclastinib + sunitinib, bezuclastinib 600mg QD + sunitinib 37.5mg QD, bezuclastinib combination
Company
COGTCogent
COGTCogentCogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486…
On the calendar
30
Nov 2026
Nov 30, 2026
in 30 days
COGTCogentTimeline
Newest first.
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT05186753 | Phase 2 | Active, not recruiting | May 22, 2025 | 237 | 24 of 57 sites in the United States |
| NCT06208748 | Phase 2 | Active, not recruiting | Jun 1, 2026 | 40 | 4 of 4 sites in the United States |
| NCT04996875 | Phase 2 | Recruiting | Sep 19, 2025 | 140 | 14 of 42 sites in the United States |